free counter with statistics
NewsVerses is the world leader in online news and information and seeks to inform, engage and empower the world.

Johnson & Johnson vaccine much less efficient in opposition to Delta variant: research

Get real time updates directly on you device, subscribe now.

A latest research from researchers at New York College discovered that the Johnson & Johnson vaccine could also be much less efficient in battling COVID-19 variants than vaccines made by Pfizer-BioNTech or Moderna. 

The outcomes of the research have been revealed by bioRxiv and have been submitted to a peer-reviewed journal. 

A registered nurse fills a syringe with the Johnson & Johnson COVID-19 vaccine at a pop up vaccination site in the Staten Island borough of New York. 

A registered nurse fills a syringe with the Johnson & Johnson COVID-19 vaccine at a pop up vaccination website within the Staten Island borough of New York.  (AP)

In accordance with the research, the mRNA-based vaccines Pfizer and Moderna have been 94 to 95% efficient in stopping COVID-19 whereas the “adenoviral vector-based” Johnson & Johnson had a roughly 67% efficient charge. 

The research was led by Nathaniel Landau, a virologist at New York College’s Grossman College of Medication. 

Landau informed Fox Information that the goal of the research “was to find out how nicely the antibodies which might be raised by the three authorized vaccines neutralize the variants of concern.” 


“The outcomes present that … all three vaccines elevate antibodies in opposition to the variants,” Landau stated. “The vaccines which have two pictures (Moderna and Pfizer) raised higher antibodies than J&J. All three vaccines are good. J&J is likely to be even higher if a second shot have been added.” 

In a press release supplied to Fox Information, Johnson & Johnson cited earlier research which confirmed {that a} single-shot of its COVID-19 vaccine was 85% vaccine “at defending in opposition to extreme illness and supplied full safety in opposition to hospitalization and loss of life.” 


The corporate stated Landau’s research didn’t communicate to the total nature of immune safety. It cited extra firm knowledge demonstrating {that a} Johnson & Johnson single-shot COVID-19 vaccine “generated robust, persistent exercise in opposition to the quickly spreading Delta variant and different extremely prevalent SARS-CoV-2 viral variants.”   

Comments are closed.